Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted) (2019 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$3.57 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 3075.0% to -$3.57 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.13 through Dec 2025, up 53.24% year-over-year, with the annual reading at -$5.02 for FY2025, 11.8% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$3.57 at Cartesian Therapeutics, down from -$1.38 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.54 in Q2 2024, with the low at -$41.56 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$3.3, with a median of -$0.19 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 3043.6% in 2022, then plummeted 83020.0% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.12 in 2021, then plummeted by 141.67% to -$0.05 in 2022, then tumbled by 83020.0% to -$41.56 in 2023, then soared by 100.29% to $0.12 in 2024, then crashed by 3075.0% to -$3.57 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$3.57, -$1.38, and $0.5 for Q4 2025, Q3 2025, and Q2 2025 respectively.